BioLife Solutions (BLFS) Investor Presentation - Slideshow

Source: Alliance for Regenerative Medicine 1H 2022 Report Active Trials by Therapy 2022 H1 Phase 1 Phase 2 ● Phase 3 Cell therapies: 46% Gene therapies: 18% 15 Accelerator of CAR-T clinical adoption To meet the current and anticipated demand in regulatory reviews and audits, the FDA is hiring 132 new staff in FY 2023 and an additional 96 in FY 2024-27 Biopreservation Challenges Customer Reimbursement Environment 18 BioLife Solutions Analysts and Investors Day March 23,2023 Cell Processing Storage and Servic ...